New Drugs for HIV Treatment and Prevention
Roy M. Gulick, MD, MPH
Rochelle Belfer Professor in Medicine
Chief, Division of Infectious Diseases
Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2024. All rights reserved.
Dr. Gulick’s research interests include designing, conducting and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the ACTG and the HIV Prevention Trials Network (HPTN), sponsored by the NIH.
At the completion of this educational activity learners will:
1. Learn about new formulations of existing antiretroviral drugs.
2. Learn about investigational drugs in existing antiretroviral drug classes.
3. Learn about investigational drugs with new mechanisms of action.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun (Course Director/Program Planner) has no relevant financial relationships to disclose.
- Dr. Kathryn Anastos, MD (Moderator) has no relevant financial relationships to disclose.
- Dr. Roy M. Gulick, MD, MPH (Presenter) has no relevant financial relationships to disclose. Dr. Gulick submitted his slides in advance for adequate peer review and supported his presentation and clinical recommendations with the best available evidence from the medical literature.
Download Article PDF/Slides